Important target classes, such as GPCRs, kinases, ion channels, and enzymes; a particularly important novel topic is orphan GPCRs, many of which have great potential as future drug targets Purinergic signaling/purinergic targets/roles of extracellular nucleosides and nucleotides A broad range of indications, in particular CNS, including neurodegenerative disorders/dementias; proteinopathies; cardiovascular diseases; metabolic diseases; kidney, liver, and bronchial diseases; inflammation, cancer, and rare diseases An important focus will be on immuno-oncology and immune diseases, including (new) checkpoint inhibitors, purine receptors, ectonucleotidases, and further innovative targets in this field Natural products and nutrition/nutraceuticals Biologicals, bioactive peptides, and macrocyclic drugs Photoswitchable drugs, light-activated drugs, and other innovative prodrugs Optopharmacology New modalities, in particular PROTACs, other chemical knockdown approaches, and antibody–drug conjugates RNA/DNA drugs and RNAs/DNAs as drug targets Diagnostics (e.g., fluorescence-based and PET ligands) Gender pharmacology Personalized medicine Structural biology Organoids in drug development High reputation: ACS is the largest scientific society in the world Broad spectrum of research High visibility, high impact High scientific and ethical standards Flexibility in initial formatting Rapid time to publication Possibility for easy transfer to other ACS journals No mandatory publication charge, color images for free ACS marketing activities Award-winning ACS Web and Mobile Editions platforms Views expressed in this editorial are those of the author and not necessarily the views of the ACS. Views expressed in this editorial are those of the author and not necessarily the views of the ACS.
This article has not yet been cited by other publications.

中文翻译：

---

加速创新药物从实验室到患者的转化：ACS 药理学和转化科学在药物研发中的发展、发展和弥合化学和生物学之间的差距

重要的目标类别，例如 GPCR、激酶、离子通道和酶；一个特别重要的新主题是孤儿 GPCR，其中许多具有作为未来药物靶点的巨大潜力 蛋白质病; 心血管疾病; 代谢疾病；肾脏、肝脏和支气管疾病；炎症、癌症和罕见疾病 重点关注免疫肿瘤学和免疫疾病，包括（新）检查点抑制剂、嘌呤受体、外核苷酸酶以及该领域的进一步创新目标 天然产品和营养/营养品 生物制品、生物活性肽、和大环药物 光敏药物、光活化药物、
这篇文章尚未被其他出版物引用。